A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness

A Double-blind Randomized Placebo Controlled Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01198106

Enrollment

100

Registered

2010-09-09

Start date

2009-09-30

Completion date

2010-09-30

Last updated

2010-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Simulator Sickness

Keywords

simulator sickness, scopolamine, cinnarizine

Brief summary

BACKGROUND:flight simulator have become an important component in pilot training. However, they are known to be associated with motion sickness like symptoms defined as Simulator Sickness (SS). Prevention countermeasures against motion sickness have been studied extensively focusing on cholinergic blockers and antihistamines. Most comparataive studies emphasized the effectiveness of scopolamine over outher agents. Evidence, though, on prophylaxis against SS is sparse. OBJECTIVE: to assess the effectiveness of oral scopolamine versus oral cinnarizine or placebo for SS prevention in helicopter pilots. DESIGN: a prospective, placebo controlled double-blind. SETTING: Israel Air Forse (IAF) Helicopter Aircaft vWeapon System Trainer. PARTICIPANTS: IAF experienced helicopter pilots. INTERVENTION: 0.6 mg oral scopolamine or 50 mg oral cinnarizine or placebo 1 hour before beginning of a 3 sortie simulator training

Interventions

DRUGscopolamine

0.6 mg

DRUGcinnarizine

50 mg

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

21 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* age 21 to 50 years, qualified helicopter pilots * history of average TS score in SSQ more than 7.48

Exclusion criteria

* known vestibular, visual or central nervous system pathology * fever of more than 37.2 degrees * any MS like symptom prior to simulator training * any compromising acute health problem

Design outcomes

Primary

Measure	Time frame	Description
Finding more effective treatment to the motion sickness symptoms during and after simulator training.	1 year	To record a significant difference in motion sickness symptoms reduction during and after simulator training, after taking cinnarizine, scopolamine or placebo. We predict that scopolamine will prove to be more effective than cinnarizine with fewer side effects that can compromise pilot's performance during training.

Countries

Israel

Contacts

Primary ContactAmit Assa, Dr.

03-7379142

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026